The firms said that the deal will provide access to Tempus' testing menu for healthcare providers at 800 cancer care locations that use Flatiron's OncoEMR platform.

NEW YORK – Autoimmune testing firm Exagen on Tuesday announced its Q3 revenues declined 7 percent year over year. For the three months ended Sept. 30, the firm posted revenues of $12.5 million, down ...

NEW YORK – AI diagnostics firm Tempus said on Tuesday that it has inked a deal with Roche's Flatiron Health that will allow healthcare providers to order Tempus' genomic cancer tests through ...